STOCK TITAN

Ligand Pharmaceuticals (LGND) Revenue by Year

LGND NASDAQ

Ligand Pharmaceuticals Inc. generated $268.1M in revenue in fiscal year 2025. This represents an increase of 60.4% from the prior fiscal year. Over the trailing 12 months, Q4 FY2025 through Q3 FY2026, the same line adds up to $253.8M in revenue. The table below carries 15 fiscal years, from 2011 to 2025, and the quarters Ligand Pharmaceuticals Inc. has filed alongside them.

FY2025 annual
Revenue $268.1M
YoY +60.4%
5Y CAGR +10.4%
10Y CAGR +14.1%
Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD

Annual figures, oldest first. Point at a bar to read its period.

LGND Revenue by Fiscal Year

Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.

MetricTTMFY2510-KFY2410-KFY2310-KFY2210-KFY2110-KFY2010-KFY1910-KFY1810-KFY1710-KFY1610-KFY1510-KFY1410-KFY1310-KFY1210-KFY1110-K
Revenue$253.8M$268.1M+60.4%$167.1M+27.3%$131.3M-33.1%$196.2M-18.8%$241.5M+47.7%$163.6M+36.0%$120.3M-52.2%$251.5M+78.2%$141.1M+29.5%$109.0M+51.5%$71.9M+11.4%$64.5M+31.8%$49.0M+56.0%$31.4M+4.5%$30.0M

TTM is the trailing twelve months, Q4 FY2025 through Q3 FY2026, summed from the four most recent quarterly filings.

LGND Revenue by Quarter

Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.

MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-QQ2'2410-QQ1'2410-QQ4'2310-K
Revenue$78.7M-31.8%$63.7M+33.7%$51.7M+14.1%$59.7M+39.4%$115.5M+122.8%$47.6M+14.7%$45.3M+46.3%$42.8M+52.4%$51.8M+57.6%$41.5M+57.5%$31.0M-29.6%$28.1M-44.2%

What revenue means

Revenue is everything the company billed its customers over the period, counted before any cost of running the business comes out of it.

More Ligand Pharmaceuticals Inc. financials

Frequently Asked Questions

What was Ligand Pharmaceuticals Inc.'s revenue in fiscal year 2025?

Ligand Pharmaceuticals Inc. generated $268.1M in revenue in fiscal year 2025.

How fast is Ligand Pharmaceuticals Inc.'s revenue growing?

Ligand Pharmaceuticals Inc. (LGND) revenue rose by 60.4% year over year, from $167.1M to $268.1M in fiscal year 2025.

What is Ligand Pharmaceuticals Inc.'s revenue over the last twelve months?

Ligand Pharmaceuticals Inc. (LGND) reported $253.8M in revenue over the trailing 12 months, Q4 FY2025 through Q3 FY2026, summed from the four most recent quarterly filings.

Across the 15 fiscal years this page covers, Ligand Pharmaceuticals Inc. (LGND) revenue went from $30.0M in fiscal year 2011 to $268.1M in fiscal year 2025.

Ligand Pharmaceuticals Inc. (LGND) reported $78.7M in revenue in Q3 2026. This represents a decrease of 31.8% from the same quarter a year earlier.

Revenue is everything the company billed its customers over the period, counted before any cost of running the business comes out of it. This page lists what Ligand Pharmaceuticals Inc. (LGND) reported on that line in every period on record.